Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Partial hepatectomy in rats carrying Reuber H-139 and H-35 hepatomas is followed by rapid growth of these tumors. At comparable times after implantation, average wet weights of H-139 or H-35 hepatomas in partially hepatectomized rats were significantly higher than average wet weights of these tumors in control rats. In H-35 hepatomas growing subcutaneously, synthesis of DNA, as shown by incorporation of tritiated thymidine, was depressed 18 hours after a two-thirds hepatectomy in the host. Between 18 and 36 hours after partial hepatectomy, DNA synthesis rose steadily, with a maximum at about 36 hours. Incorporation of (14)C-leucine into ferritin (apoferritin) reached a maximum in liver and, to less extent, also in subcutaneous H-35 hepatomas, 48 hours after partial hepatectomy and returned to normal levels at 72 hours. The increase in wet weight of the tumors is most likely the result of an increase in rate of growth concomitant with the restoration of liver mass. The rise in synthesis of DNA and of ferritin in hepatoma cells after partial hepatectomy suggests that these hepatomas were affected by the same humoral factor or mechanism that stimulates cell division and protein synthesis in the liver immediately after partial hepatectomy.
 ...
PMID:Effects of partial hepatectomy in rats on two transplantable hepatomas. Changes in weight and in synthesis of DNA and ferritin. 433 95

Results of dosimetric studies are reported for 30 patients with hepatoma and 5 patients with primary hepatic cholangiocarcinoma who received treatment with 131I-labeled polyclonal antibodies. Studies included liver and tumor volume computations from X-ray CT scans, in vivo quantitation of the activity of radiolabeled antibodies in hepatic tumors and normal liver tissue, and effective half-life measurements. Twenty-two patients with hepatoma were administered 131I-labeled polyclonal anti-ferritin. Five hepatoma patients, who were AFP-positive, were administered anti-alpha-fetoprotein (AFP). Three patients with AFP-positive hepatomas received both 131I-labeled anti-ferritin and anti-AFP in a bolus. The five cholangiocarcinoma patients were treated with 131I-labeled anti-carcinoembryonic antigen (CEA). For administered activities of 30 mCi on day 0 and 20 mCi on day 5, mean values of the radiation dose to hepatomas were approximately 1100 rads for anti-ferritin, 350 rads for anti-AFP, and 960 rads for the combination of anti-ferritin and anti-AFP. Polyclonal anti-ferritin has, therefore, become the antibody of choice in the treatment of hepatoma. The radiation dose to cholangiocarcinomas from 131I-labeled anti-CEA and administered activities of 20 mCi on day 0 and 10 mCi on day 5 was approximately 620 rads. Total-body irradiation for these injection schedules ranged from 30 to 50 rads.
 ...
PMID:Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers. 608 56

Ferritin was extracted from human hepatocellular carcinoma tissue and purified using column chromatography, gradient gel electrophoresis and cadmium sulphate crystallization. DEAE cellulose chromatography showed a difference between hepatoma and normal liver ferritin, indicative of a more acidic isoferritin profile in the tumour. Column-purified and crystalline ferritin and that remaining in the mother-liquor after crystallization was subjected to isoelectric focusing. Hepatoma ferritin showed higher concentrations of acidic isoferritins than liver ferritin. This was most obvious with mother-liquor ferritin, as crystallization tended to select out more basic isoferritins. Subunit analysis of hepatoma and liver ferritin showed a higher proportion of heavy subunits in the tumour ferritin, in keeping with the presence of acidic isoferritins. An antibody against hepatoma mother-liquor ferritin was raised in rabbits. However, hepatoma ferritin proved to be antigenically identical with normal liver ferritin, and we were thus unable to develop a specific radioimmunoassay for hepatoma ferritin.
 ...
PMID:Isolation of ferritin from human hepatocellular carcinoma. 609 60

Serum ferritin was studied in 4 patients with abdominal Burkitt's lymphoma, 6 with facial Burkitt's lymphoma, 10 with primary hepatocellular carcinoma, 6 with secondary hepatic cancer, 8 with primary breast cancer, 4 with Hodgkins's disease, 3 with chronic lymphocytic leukaemia and 6 with other neoplastic diseases. Control values were determined for 23 apparently healthy Nigerians. Serum ferritin was significantly elevated in patients with Burkitt's lymphoma (facial and abdominal combined), primary hepatocellular carcinoma, secondary hepatic cancer, chronic lymphocytic leukaemia (p less than 0.00001), Hodgkin's disease and in other neoplastic diseases as compared to the control (p less than 0.0004). Serum ferritin levels were significantly elevated (p less than 0.00001) in abdominal Burkitt's lymphoma but less dramatically elevated values or even values within the reference range (mean + 2 Standard Deviations of the controls) were seen in the values of serum ferritin in the patients with facial Burkitt's lymphoma. The assay of serum ferritin may be of some value in the diagnosis and classification of patients with Burkitt's lymphoma, and in monitoring the treatment provided.
 ...
PMID:Serum ferritin in Nigerian patients with Burkitt's lymphoma and other malignant diseases. 613 56

The serum ferritin level was raised in 34 of 35 (97%) patients with hepatocellular carcinoma and in 20 of 23 (87%) with uncomplicated cirrhosis. Levels rose following therapeutic embolisation in 14 of 15 patients and continued to rise in 85% of all tumor patients who showed no clinical response to chemotherapy (intravenous Adriamycin) whereas in those who did respond the serum ferritin level fell. By contrast, there was a fall in serum alphafetoprotein immediately after embolisation but like serum ferritin, alphafetoprotein levels rose with disease progression and only fell in those achieving clinical remission. Serum ferritin has no role in the differential diagnosis of hepatocellular carcinoma but may be a useful marker in monitoring response to chemotherapy particularly in the alphafetoprotein-negative patient.
 ...
PMID:Serum ferritin in hepatocellular carcinoma. A comparison with alphafetoprotein. 618 26

Serum ferritin levels were studied in 264 patients who were consisted of 153 patients with various malignant neoplasms and 111 patients with various benign diseases. Positive rate of serum ferritin in all patients with malignant neoplasms was 35%. Hepatomas and pulmonary cancer showed relatively high positive rate, respectively 65% and 42%. In patients with benign diseases, hepatic diseases showed the high positive rate (52%) and the other benign diseases was low positive rate (11%). The relationship between serum ferritin and alpha-feto-protein in patients with hepatomas and other liver diseases was low. And the relationship between serum ferritin and CEA (carcinoembryonic antigen) in patients with malignant neoplasms of gastrointestinal tract was also low. It seemed that the measurement of serum ferritin levels will be of low value in the differentiation of the patients with malignant neoplasms.
 ...
PMID:[Serum ferritin in patients with malignant neoplasms]. 619 Jan 99

The Con A-peroxidase reaction has demonstrated glycoproteins with molecular masses of 200 and 50 kilodalton on the polyacrylamide gel-SDS electrophoregrams of the molecular matrices isolated from rat liver, hepatoma 27 and Zajdela's ascites hepatoma. Both hepatomas contained an additional band of about 38 kilodalton, whereas Zajdela's hepatoma distinct bands of 54 kilodalton and less demonstrable of over 200 and about 105 and 68 kilodalton. Electron microscopy showed Con A-ferritin staining, more prominent in hepatomas than in the liver, at the periphery of isolated nuclear matrix preparations. Ruthenium red staining characteristic of acidic polysaccharides (glycosaminoglycans), on the contrary, was more pronounced in liver nuclear matrices.
 ...
PMID:[Carbohydrate components of the nuclear matrix in rat liver and hepatoma]. 619 9

We evaluated whether assay of tissue polypeptide antigen (TPA) in sera is valuable for the determination of cancer stages compared to other tumor markers such as CEA, AFP, beta2-microglobulin, ferritin, and elastase-1. The study population consisted of cancer patients (33 gastric cancers, 7 colo-rectal cancers and 15 hepatomas), 169 patients with benign gastro-enteric diseases and 72 healthy volunteers. The percentage of positive cases for TPA (higher than 200 u/l) was 61% in gastric cancer, 71% in colo-rectal cancer and 87% in hepatoma. In certain non-cancerous conditions, such as gastric ulcer (active stage), acute hepatitis and chronic hepatitis, the TPA levels were increased over the level of healthy volunteers. There was no significant correlation between TPA and the other tumor markers. Our study suggests that TPA may be useful in the identification and evaluation of cancer patients.
 ...
PMID:[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]. 620 29

The clinical significance of serum ferritin as a serological marker of hepatocellular carcinoma (HCC) was studied. Fasting serum ferritin levels were measured in 343 patients with diseases of the liver, using a radioimmunoassay ferritin kit. Elevated ferritin levels were obtained in various liver diseases but hyperferritinemia could be more clearly interpreted by classifying ferritin levels according to serum iron or transaminase values. Significantly higher values were obtained in HCC than liver cirrhosis. Sensitivity for diagnosis of HCC increased by serial and simultaneous determinations of ferritin and alpha-fetoprotein because high ferritin levels were observed more often in low alpha-fetoprotein-producing HCC and also in HBsAg negative, alcohol related, small-sized HCC. Therefore, simultaneous determination of alpha-fetoprotein and ferritin seems to be useful for detection of HCC in high risk patients such as those with liver cirrhosis.
 ...
PMID:Clinical significance of serum ferritin determination for hepatocellular carcinoma. 620 85

The diagnostic value of serum ferritin levels was evaluated in 19 patients with biopsy-proven primary hepatocellular carcinoma (PHC) and 26 patients with chronic liver disease (CLD). Serum ferritin levels were significantly elevated in PHC, as compared with CLD and controls (p less than 0.0005). Similarly, serum ferritin/SGOT ratio, an index of increased ferritin production, was significantly higher in PHC than in CLD and controls. Serum alpha-fetoprotein (alpha-FP) was higher in PHC than in CLD (p less than 0.0025). No significant correlation was noted between serum ferritin and alpha-fetoprotein or SGOT in PHC and CLD. 17 of 19 patients with PHC had serum ferritin values over 450 ng/ml (sensitivity 88%). By contrast, only 10 of 17 patients with PHC (59%) demonstrated alpha-FP levels over 25 ng/ml, compatible with the diagnosis of PHC. 9 of these 10 patients had ferritin levels over 450 ng/ml, within the distribution of values for PHC. Conversely, 7 of 17 patients with PHC (40%) had normal levels of alpha-FP (false-negative). However, 6 of these patients (86%) had ferritin levels over 450 ng/ml, consistent with values in PHC. In this study, the overall sensitivity of serum ferritin in PHC was higher than that of alpha-FP (88 versus 59%) and its specificity 85 versus 68% for alpha-FP. These data indicate that serum ferritin may be utilized as a useful diagnostic marker in the evaluation of patients with PHC.
 ...
PMID:Diagnostic value of serum ferritin in primary hepatocellular carcinoma. 621 Feb 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>